Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis.
The case histories of five patients initially resistant to Glucantime therapy are presented. In addition comments are made on each patient since they demonstrated unusual clinical features. The practical difficulties in assessing true resistance to Glucantime are briefly discussed.
D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000941:Antigens / Q000276:immunology; D000965:Antimony / Q000627:therapeutic use*; D001938:Brazil; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007891:Leishmania / Q000276:immunology; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy* / Q000276:immunology; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds; D013012:Sorbitol / Q000031:analogs & derivatives*
D000941:Antigens; D009942:Organometallic Compounds; D013012:Sorbitol; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B; D000965:Antimony